PRCT Stock Price, PROCEPT BioRobotics Quote, Chart

Market Summary

USD68.19+0.05

Delayed

0.07%

PRCT Alerts

2 major insider sales recently.

Big jump in Revenue (Y/Y)
Losses in recent quarter

PRCT Stock Price

View Fullscreen

PRCT RSI Chart

PRCT Valuation

Market Cap

3.5B

Price/Earnings (Trailing)

-33.92

Price/Sales (Trailing)

22.43

Price/Free Cashflow

-27.79

PRCT Price/Sales (Trailing)

PRCT Profitability

Operating Margin

53.47%

Return on Equity

-39.15%

Return on Assets

-27%

Free Cashflow Yield

-3.6%

PRCT Fundamentals

PRCT Revenue

Revenue (TTM)

156.3M

Rev. Growth (Yr)

82.51%

Rev. Growth (Qtr)

2.2%

PRCT Earnings

Earnings (TTM)

-103.4M

Earnings Growth (Yr)

8.87%

Earnings Growth (Qtr)

5.63%

Breaking Down PRCT Revenue

Last 7 days

8.8%

Last 30 days

31.7%

Last 90 days

36.5%

Trailing 12 Months

107.7%

How does PRCT drawdown profile look like?

PRCT Financial Health

Current Ratio

8.52

Debt/Equity

0.19

Debt/Cashflow

-2.03

PRCT Investor Care

Shares Dilution (1Y)

14.15%

Diluted EPS (TTM)

-2.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	156.3M	0	0	0
2023	85.2M	101.6M	116.4M	136.2M
2022	41.5M	49.7M	61.4M	75.0M
2021	14.4M	21.1M	27.8M	34.5M
2020	0	0	0	7.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of PROCEPT BioRobotics Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	mcgaughy r kent jr	sold	-	-	-1,785,130	-
May 03, 2024	nouri alaleh	acquired	208,978	6.86705	30,432	evp, clo, corp. sec.
May 03, 2024	nouri alaleh	sold	-1,916,430	62.9741	-30,432	evp, clo, corp. sec.
May 03, 2024	desai antal rohit	sold	-	-	-1,785,130	-
May 01, 2024	krummel thomas m	sold	-1,200,000	60.00	-20,000	-
Apr 18, 2024	wood larry l	acquired	-	-	3,054	-
Mar 18, 2024	waters kevin	sold	-50,001	48.83	-1,024	evp, cfo
Mar 18, 2024	nouri alaleh	sold	-21,534	48.83	-441	evp, clo, corp. sec.
Mar 18, 2024	zadno reza	sold	-263,243	48.83	-5,391	president, ceo
Mar 18, 2024	shiblaq hisham	sold	-11,914	48.83	-244	evp, chief comm. officer

Which funds bought or sold PRCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-58.31	-3,101,820	2,999,650	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-3.35	272,220	2,220,490	-%
May 16, 2024	CASTLEARK MANAGEMENT LLC	new	-	2,841,160	2,841,160	0.12%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	0.01	137,855	914,394	-%
May 15, 2024	BARCLAYS PLC	reduced	-41.64	-841,000	1,857,000	-%
May 15, 2024	D. E. Shaw & Co., Inc.	added	649	8,234,030	9,284,040	0.01%
May 15, 2024	Point72 (DIFC) Ltd	new	-	53,431	53,431	-%
May 15, 2024	AlTi Global, Inc.	unchanged	-	495,254	3,259,050	0.09%
May 15, 2024	Point72 Europe (London) LLP	reduced	-39.55	-6,379,580	15,835,700	1.41%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-92.35	-244,302	24,216	-%

Are Funds Buying or Selling PRCT?

Are funds buying PRCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PRCT

No. of Funds

Unveiling PROCEPT BioRobotics Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 07, 2024	cpmg inc	6.3%	3,222,345	SC 13D/A
Feb 14, 2024	t. rowe price investment management, inc.	7.3%	3,695,027	SC 13G
Feb 13, 2024	vanguard group inc	8.29%	4,184,585	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	6.6%	3,357,638	SC 13G
Feb 14, 2023	viking global investors lp	0.0%	0	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	6.0%	2,697,885	SC 13G
Feb 09, 2023	vanguard group inc	7.23%	3,234,864	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Dec 07, 2022	cpmg inc	11.9%	5,328,867	SC 13D/A

Recent SEC filings of PROCEPT BioRobotics Corporation

View All Filings

Date Filed	Form Type	Document
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	SC 13D/A	13D - Major Acquisition
May 03, 2024	144	Notice of Insider Sale Intent
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	8-K	Current Report
May 02, 2024	10-Q	Quarterly Report
May 01, 2024	144	Notice of Insider Sale Intent
May 01, 2024	8-K	Current Report

Peers (Alternatives to PROCEPT BioRobotics Corporation)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

PROCEPT BioRobotics Corporation News

Latest updates

PROCEPT BioRobotics Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	2.2%	45.00	44.00	35.00	33.00	24.00	24.00	20.00	17.00	14.00	10.00	9.00	8.00	7.00	5.00	2.00
Cost Of Revenue	-12.6%	20.00	22.00	16.00	15.00	12.00	13.00	10.00	8.00	7.00	6.00	4.00	5.00	4.00	-	2.00
Gross Profit	17.8%	25.00	21.00	19.00	18.00	12.00	11.00	10.00	8.00	8.00	5.00	4.00	4.00	4.00	-	-0.03
Operating Expenses	3.7%	53.00	51.00	44.00	44.00	41.00	36.00	32.00	26.00	23.00	21.00	17.00	17.00	15.00	-	11.00
S&GA Expenses	9.0%	40.00	36.00	33.00	32.00	30.00	26.00	25.00	20.00	18.00	16.00	12.00	12.00	10.00	-	7.00
R&D Expenses	-9.7%	13.00	14.00	12.00	12.00	11.00	10.00	8.00	7.00	5.00	5.00	5.00	4.00	5.00	-	4.00
Interest Expenses	-7.1%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	1.00
Net Income	5.6%	-25.96	-27.50	-24.62	-25.28	-28.48	-28.17	-22.61	-19.18	-17.18	-18.35	-14.10	-14.58	-12.82	-15.28	-12.01
Net Income Margin	15.0%	-0.66*	-0.78*	-0.92*	-1.03*	-1.16*	-1.16*	-1.26*	-1.38*	-1.55*	-1.74*	-2.04*	-2.59*	-3.66*	-6.87*	-
Free Cashflow	-2.2%	-34.23	-33.51	-24.72	-33.71	-41.27	-26.04	-21.36	-17.34	-18.29	-16.81	-12.86	-13.02	-15.24	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-5.4%	383	405	421	272	284	309	324	311	321	337	351	126
Current Assets	-6.1%	329	351	369	230	246	273	289	298	308	326	339	110
Cash Equivalents	-11.1%	229	257	287	150	181	222	249	270	284	304	320	101
Inventory	4.7%	42.00	40.00	42.00	43.00	39.00	29.00	22.00	14.00	13.00	13.00	10.00	7.00
Net PPE	-0.9%	28.00	29.00	27.00	16.00	12.00	9.00	5.00	4.00	5.00	5.00	6.00	8.00
Liabilities	-4.1%	119	124	122	117	111	112	103	72.00	68.00	70.00	68.00	65.00
Current Liabilities	-15.8%	39.00	46.00	41.00	36.00	33.00	35.00	27.00	19.00	15.00	16.00	14.00	15.00
Long Term Debt	0.1%	51.00	51.00	51.00	51.00	51.00	51.00	51.00	51.00	50.00	50.00	50.00	44.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	5.00
LT Debt, Non Current	-100.0%	-	51.00	51.00	51.00	51.00	51.00	51.00	51.00	50.00	50.00	50.00	44.00
Shareholder's Equity	-6.0%	264	281	299	156	173	197	221	239	253	267	283	-
Retained Earnings	-5.7%	-480	-454	-427	-402	-377	-348	-320	-297	-278	-261	-243	-201
Additional Paid-In Capital	1.3%	744	735	726	558	550	546	541	537	532	529	527	19.00
Accumulated Depreciation	30.9%	5.00	4.00	-	-	-	9.00	-	-	7.00	7.00	6.00	5.00
Shares Outstanding	1.2%	51.00	51.00	50.00	45.00	45.00	44.00	44.00	44.00	44.00	16.00	7.00	5.00
Float	-	-	-	-	1,400	-	-	-	1,000	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-30.2%	-32,286	-24,793	-18,943	-28,339	-35,928	-25,174	-19,851	-17,126	-18,231	-16,476	-12,751	-12,909	-15,198	-	-
Share Based Compensation	25.6%	6,256	4,981	5,326	5,103	3,724	2,885	3,224	2,676	1,552	1,496	925	725	650	-	-
Cashflow From Investing	77.7%	-1,946	-8,715	-5,780	-5,372	-5,339	-866	-1,514	-218	-55.00	-332	-111	-110	-39.00	-	-
Cashflow From Financing	-9.8%	2,586	2,866	162,119	2,430	380	-1,318	777	2,862	1,291	644	174,122	86,125	1,225	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PRCT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 44,539	$ 24,404
Cost of sales	19,505	11,913
Gross profit	25,034	12,491
Operating expenses:
Research and development	13,084	10,737
Selling, general and administrative	39,599	30,131
Total operating expenses	52,683	40,868
Loss from operations	(27,649)	(28,377)
Interest expense	(1,045)	(886)
Interest and other income, net	2,737	779
Net loss	$ (25,957)	$ (28,484)
Net loss per share, basic (in dollars per share)	$ (0.51)	$ (0.63)
Net loss per share, diluted (in dollars per share)	$ (0.51)	$ (0.63)
Weighted-average common shares used to compute net loss per share attributable to
Common shareholders, Basic (in shares)	51,011	45,066
Common shareholders, Diluted (in shares)	51,011	45,066
Other comprehensive loss:
Unrealized gain on cash equivalents	$ 29	$ 21
Comprehensive loss	$ (25,928)	$ (28,463)

PRCT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 225,576	$ 257,222
Accounts receivable, net	56,081	48,376
Inventory	41,622	39,756
Prepaid expenses and other current assets	5,907	5,213
Total current assets	329,186	350,567
Restricted cash, non-current	3,038	3,038
Property and equipment, net	28,488	28,748
Operating lease right-of-use assets, net	19,892	20,241
Intangible assets, net	1,136	1,204
Other assets	1,160	919
Total assets	382,900	404,717
Current liabilities:
Accounts payable	10,084	13,499
Accrued compensation	11,469	16,885
Deferred revenue	5,860	5,656
Operating lease, current	1,701	1,683
Loan facility derivative liability, current	1,914	1,886
Other current liabilities	7,622	6,318
Total current liabilities	38,650	45,927
Long-term debt	51,371	51,339
Operating lease, non-current	28,315	26,182
Other liabilities	517	517
Total liabilities	118,853	123,965
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, $0.00001 par value; Authorized shares: 10,000 at March 31, 2024 and December 31, 2023, Issued and outstanding shares: none at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.00001 par value; Authorized shares: 300,000 at March 31, 2024 and December 31, 2023 Issued and outstanding shares: 51,393 and 50,771 at March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in capital	744,463	735,240
Accumulated other comprehensive gain	113	84
Accumulated deficit	(480,529)	(454,572)
Total stockholders’ equity	264,047	280,752
Total liabilities and stockholders’ equity	$ 382,900	$ 404,717

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

CEO	Dr. Reza Zadno Ph.D.
WEBSITE	procept-biorobotics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	428

PROCEPT BioRobotics Corporation Frequently Asked Questions

What is the ticker symbol for PROCEPT BioRobotics Corporation? What does PRCT stand for in stocks?

PRCT is the stock ticker symbol of PROCEPT BioRobotics Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PROCEPT BioRobotics Corporation (PRCT)?

As of Fri May 17 2024, market cap of PROCEPT BioRobotics Corporation is 3.51 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRCT stock?

You can check PRCT's fair value in chart for subscribers.

What is the fair value of PRCT stock?

You can check PRCT's fair value in chart for subscribers. The fair value of PROCEPT BioRobotics Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PROCEPT BioRobotics Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PROCEPT BioRobotics Corporation a good stock to buy?

The fair value guage provides a quick view whether PRCT is over valued or under valued. Whether PROCEPT BioRobotics Corporation is cheap or expensive depends on the assumptions which impact PROCEPT BioRobotics Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRCT.

What is PROCEPT BioRobotics Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PRCT's PE ratio (Price to Earnings) is -33.92 and Price to Sales (PS) ratio is 22.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRCT PE ratio will change depending on the future growth rate expectations of investors.